Skip to main content

Advertisement

SpringerLink
Log in

BRAF V600E Mutation Analysis in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-time PCR

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

ABSTRACT

Background

Activating somatic mutation of the BRAF V600E has been identified as the most common genetic event in papillary thyroid carcinoma (PTC) with a variable frequency (32–87 %) in different series by different methods. The BRAF V600E mutation is associated with various clinicopathological parameters. The mutation is an important factor for the management of the PTC patients. The objective of this study was to detect the BRAF V600E mutation in PTCs by peptide nucleic acid (PNA) clamp real-time PCR and to analyze the results with clinicopathological parameters.

Methods

We performed genetic analysis of BRAF V600E by PNA clamp real-time PCR in 211 PTCs in Korea, stratified by clinicopathological parameters.

Results

The BRAF V600E mutation was detected in 90 % of PTC cases, and it occurred significantly more often in female patients than in male patients (p = 0.001). The clinicopathological parameters of age, tumor size, and disease stage were not associated with the BRAF V600E mutation, while extrathyroid invasion (p = 0.031), lymph nodal metastasis (p = 0.002), and tumor multiplicity (p = 0.020) were.

Conclusions

The prevalence (90 %) of the BRAF V600E mutation in this study is the highest ever reported, confirming the key role of this mutation in PTC tumorigenesis. The BRAF V600E mutation was associated with aggressive clinical behaviors including extrathyroid invasion, lymph nodal metastasis and tumor multifocality. The PNA clamp real-time PCR method for the BRAF V600E mutation detection is sensitive and is applicable in a clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

REFERENCES

  1. Paterson IC, Greenlee R, Adams Jones D. Thyroid cancer in Wales, 1985–1996: a cancer registry–based study. Clin Oncol (R Coll Radiol). 1999;11:245–51.

    Article  CAS  Google Scholar 

  2. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–7.

    PubMed  CAS  Google Scholar 

  3. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–7.

    Article  PubMed  CAS  Google Scholar 

  4. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561–7.

    PubMed  CAS  Google Scholar 

  5. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455–7.

    Article  PubMed  CAS  Google Scholar 

  6. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.

    Article  PubMed  CAS  Google Scholar 

  7. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004;61:239–43.

    Article  CAS  Google Scholar 

  8. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818–21.

    PubMed  CAS  Google Scholar 

  9. Nakamura N, Carney JA, Jin L, et al. RASSF1A and NORE1A methylation and BRAF V600E mutations in thyroid tumors. Lab Invest. 2005;85:1065–75.

    Article  PubMed  CAS  Google Scholar 

  10. Kebebew E, Weng J, Bauer J, et al. The prevalence of prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466–71.

    Article  PubMed  Google Scholar 

  11. Vasil’ev EV, Roumiantsev PO, Saenko VA, et al. Molecular analysis of structural abnormalities in papillary thyroid carcinoma genome. Mol Biol. 2004;38:538–48.

    Article  Google Scholar 

  12. Gu LQ, Li FY, Zhao L, et al. BRAF V600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid. 2009;19:347–54.

    Article  PubMed  CAS  Google Scholar 

  13. Nam JK, Jung CK, Song BJ, et al. Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012;203:436–41.

    Article  PubMed  CAS  Google Scholar 

  14. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–7.

    PubMed  CAS  Google Scholar 

  15. Puxeddu E, Moretti S, Elisei R, et al. BRAF V599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:2414–20.

    Article  PubMed  CAS  Google Scholar 

  16. Perren A, Schmid S, Locher T, et al. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer. 2004;11:855–60.

    Article  PubMed  CAS  Google Scholar 

  17. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of thyroid papillary carcinoma. J Pathol. 2004;202:247–51.

    Article  PubMed  CAS  Google Scholar 

  18. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578–80.

    Article  PubMed  CAS  Google Scholar 

  19. Sykorova V, Dvorakova S, Ryska A, et al. BRAF V600E mutation in the pathogenesis of the large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest. 2010;33:318–24.

    PubMed  CAS  Google Scholar 

  20. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.

    Article  PubMed  CAS  Google Scholar 

  21. Rowe LR, Bentz BG, Bentz JS. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clinl Pathol. 2007;60:1211–5.

    Article  CAS  Google Scholar 

  22. Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg. 2006;244:799–804.

    Article  PubMed  Google Scholar 

  23. Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006;154:341–8.

    Article  PubMed  CAS  Google Scholar 

  24. Hayashida N, Namba H, Kumagai A, et al. A rapid and simple detection method for the BRAF T1796A mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid. 2004;14:910–5.

    Article  PubMed  CAS  Google Scholar 

  25. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF V600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19:137–41.

    Article  PubMed  Google Scholar 

  26. Lyon E, Wittwer CT. LightCycler technology in molecular diagnostics. J Mol Diagn. 2009;11:93–101.

    Article  PubMed  CAS  Google Scholar 

  27. Demers DB, Curry ET, Egholm M, Sozer AC. Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA). Nucleic Acids Res. 1995;23:3050–5.

    Article  PubMed  CAS  Google Scholar 

  28. Jeong D, Jeong Y, Lee J, et al. Rapid and sensitive detection of KRAS mutation by peptide nucleic acid–based real-time PCR clamping: a comparison with direct sequencing between fresh tissue and formalin-fixed and paraffin embedded tissue of colorectal cancer. Korean J Pathol. 2011;45:151–9.

    Article  Google Scholar 

  29. Kyger EM, Krevolin MD, Powell MJ. Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. Anal Biochem. 1998;260:142–8.

    Article  PubMed  CAS  Google Scholar 

  30. Taback B, Bilchik AJ, Saha S, et al. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer. 2004;111:409–14.

    Article  PubMed  CAS  Google Scholar 

  31. Thiede C, Bayerdörffer E, Blasczyk R, Wittig B, Neubauer A. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res. 1996;24:983–4.

    Article  PubMed  CAS  Google Scholar 

  32. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612–7.

    Article  PubMed  CAS  Google Scholar 

  33. Kim JY, Moon SJ, Kim KR, et al. Dietary iodine intake and urinary iodine excretion in normal Korean adults. Yonsei Med J. 2000;39:355–62.

    Google Scholar 

  34. Kim JY, Kim KR. Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. Yonsei Med J. 2000;41:22–8.

    PubMed  CAS  Google Scholar 

  35. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globocan 2008 v1.2, Cancer incidence and mortality worldwide. IARC CancerBase 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.

  36. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6388S–92S.

    Article  PubMed  CAS  Google Scholar 

  37. Sala E, Mologni L, Truffa S, Gactano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008;6:751–9.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENT

We thank the Gene Bank of Soonchunhyang University for providing materials for this research.

Author information

Authors and Affiliations

  1. Department of Pathology, Soonchunhyang University College of Medicine, Cheonan City, Republic of Korea

    Dongjun Jeong PhD, Yujun Jeong MS, Soyoung Park MS, Hyun Deuk Cho MD, PhD, Mee Hye Oh MD, PhD, Seung Ha Yang MD, PhD & Chang Jin Kim MD, PhD

  2. Division of Breast and Endocrine Surgery, Department of Surgery, Soonchunhyang University, Cheonan Hospital, Cheonan City, Republic of Korea

    Ji Hye Park MD, Sun Wook Han MD & Sung Yong Kim MD, PhD

  3. Division of Endocrinology, Department of Internal Medicine, Soonchunhyang University, Cheonan Hospital, Cheonan City, Republic of Korea

    Yeo Joo Kim MD, PhD & Sang Jin Kim MD, PhD

  4. Department of Preventive Medicine, Soonchunhyang University College of Medicine, Cheonan City, Republic of Korea

    Young Hwangbo MD, PhD

Authors
  1. Dongjun Jeong PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yujun Jeong MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ji Hye Park MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sun Wook Han MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sung Yong Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yeo Joo Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sang Jin Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Young Hwangbo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Soyoung Park MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hyun Deuk Cho MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mee Hye Oh MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Seung Ha Yang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Chang Jin Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chang Jin Kim MD, PhD.

Additional information

Dongjun Jeong and Yujun Jeong have contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeong, D., Jeong, Y., Park, J.H. et al. BRAF V600E Mutation Analysis in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-time PCR. Ann Surg Oncol 20, 759–766 (2013). https://doi.org/10.1245/s10434-012-2494-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2494-0

Keywords

Search

Navigation